Janssen Biotech, Inc. obtained publication of European Patent Application EP3760230A1 covering human anti-IL-23 antibodies, compositions comprising said antibodies, and methods of therapeutic use. The application claims priority across multiple therapeutic indications including A61P classifications for gastrointestinal (A61P1/00, A61P1/04), dermatological (A61P17/06, A61P17/08), musculoskeletal (A61P19/02), neurological (A61P25/00, A61P25/02), ophthalmological (A61P27/02), immunological (A61P37/00, A61P37/02), and oncological (A61P35/00) conditions. The six named inventors are Benson, Carton, Cunningham, Orlovsky, Rauchenberger, and Sweet.

Patent publications do not create immediate compliance obligations but establish intellectual property rights that may affect market entry strategies for competing IL-23 targeted therapies. Generic manufacturers and biosimilar developers should monitor this patent for freedom-to-operate considerations when developing similar products for the designated European territories. No opposition period or compliance deadlines are associated with this publication notice.